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Introduction
Basal-Like Breast Cancer (BLBC) accounts for 13% of all breast carcinomas [1] . It is characterized by a unique mRNA profile with CK5/6 expression, inactivation of BRCA1 and lack of estrogen receptor and HER-2 amplification [1] [2] [3] . BLBC is considered one of the most aggressive, metastatic, and chemoresistant breast cancer subtypes [4] . Its poor prognosis is linked to enrichment for tumor initiating cancer stem cells (CSC) [5] . The Cancer Stem Cell Model suggests that tumors, similar to normal tissue, are organized in a cellular hierarchy, with (CSC) at the top, as the cells with potentially limitless proliferation abilities [6] . The more 'differentiated' descendants, which account for the majority of the tumor population, may also be able to proliferate, but regenerative ability is limited [6] . Traditional chemotherapy agents target these differentiated cells, but unfortunately fail to kill the stem cell progenitor population [7] . The chemoresistant stem cells are thought to be responsible for relapse and metastasis of many tumor types [7] . Several investigators have shown that BLBC cell lines and patient samples contain a subpopulation of breast cancer stem cells (BrCSC) [8, 9] . These BrCSC are identified based on their enhanced tumorigenicity, tumorsphere forming ability, expression of CD44 + /CD24 -, elevated enzymatic activity of aldehyde dehydrogenase (ALDH), and dysregulation of self-renewing pathways, including Wnt, Hedgehog, and Notch signaling [10, 11] . BrCSC also overexpress ABC efflux transporters, detoxification enzymes, and have slower turnover rate that make this sub-population likely to become resistant to chemotherapy [12, 13] . Thus an effective BLBC therapeutic strategy must kill these propagating and chemoresistant BrCSC in addition to the proliferating non-stem cell cancer population [14] .
One promising approach to prevent BLBC recurrence and metastasis is to target pathways that regulate tumor initiation such as the Wnt/β-catenin pathway [4, 15] . A cell surface receptor called LRP6, essential for Wnt/β-catenin signaling, is a potential target because its expression is frequently up-regulated in 20-36% of human breast cancers. Furthermore, suppression of LRP6 is sufficient to inhibit Wnt signaling in breast cancer [16] . Specifically in BLBC, LRP6 is expressed at elevated levels not seen in any other breast cancer subtype, thus providing an excellent potential target for treatment [15] [16] [17] [18] . The Wnt/β-catenin pathway can be inhibited by Niclosamide, which degrades LRP6 and interacts with Frizzled thus preventing proliferation and causing apoptosis [19] [20] [21] . Niclosamide (trade name Niclocide) is a teniacide in the antihelminth family that has been FDA approved for the treatment of tapeworms and has been used in humans for nearly 50 years [22] [23] [24] . Niclosamide has also been shown to be cytotoxic against prostate and colorectal cancer, myelogenous leukemia, and in ovarian cancer it suppresses CSC and metastasis [21, [25] [26] [27] . TRAIL (tumor necrosis factor-related apoptosisinducing ligand) also inhibits Wnt/β-catenin signaling by promoting caspase 3 and 8 mediated cleavage of β -catenin [28, 29] . TRAIL also induces apoptosis in BLBC, however, these promising aspects of TRAIL have been mitigated by the hepatic cytotoxicity seen with some TRAIL preparations [30, 31] . TRA-8 is a non-hepatotoxic agonistic monoclonal antibody (mAb) to TRAIL death receptor 5 (DR5) [32, 33] . BLBC, are preferentially sensitive to TRA-8 induced apoptosis; however, some BLBC cells lines are resistant to treatment [34] . My hypothesis is that suppression of Wnt activity by Niclosamide will further sensitize BLBC and its CSC population to treatment with TRA-8. Task 1a and 1b have been completed. Detailed results were reported in the 2011 annual report. The summary of previous results pertinent for this report are the identification and characterization of non-adherent tumorsphere enriched (NATE) cells from BLBC cell lines. NATE cells were identified from freshly formed tumorspheres and were compared to adherent cells that were sorted for the CSC marker, ALDH + , at 6, 12 and 24 h. From this, NATE cells were identified within the newly formed tumorspheres. NATE cells showed 70-80% enrichment for ALDH activity at the 12 h time point compared to sorted ALDH + cells. In the 2LMP, SUM159, and HCC1143 cell lines, ALDH activity was lost over time for both sorted and NATE cells (Fig. 1A) . NATE cells (obtained from the tumorspheres at the 12 h time point) showed an enhanced ability to form tumors after mammary fat pad injection (MFP) injection of 20,000 cells in NOD/SCID mice compared to non-adherent cells (obtained from tumorspheres after they had been in non-adherent culture for 4 days). The NATE cells formed aggressive large tumors faster then the non-adherent cells (Fig. 1B ) (p=0.01). NATE cells were generated as a tool to analyze the effect of drugs on CSC enriched populations. Because CSCs represent a small fraction of the total population, it is difficult to run mechanistic studies with these cells especially by techniques such as Western blot and TOPflash reporter assay that require a large number of cells. The isolation of NATE cells allowed us to test these novel drug combinations on a larger scale. Further studies need to be conducted to better understand what epigenetic alterations such as EMT/MET are occurring to enrich for this transient CSC population [35] . Non-adherent cells alone do not represent an aggressive population. Also, patient pleural effusion samples were characterized by immunohistochemistry for positive Moc31 staining (adenocarcinoma) and negative Calretinin staining (mesothelial cells) (Figure 2 (Fig. 3 ). All four patient pleural effusion samples showed greater then 50% reduction in viability. Patient sample UAB05 did not show a dose response past 50% and patient sample UAB04 reached 70% reduction at the lowest dose but also did not show a dose response. UAB03 and UAB01 both reached a 70% reduction in viability with the lowest does of 1 µM and showed a dose response with two-fold increasing concentrations of Niclosamide (Fig. 4C) .
Specific Aims
Task 3b. Niclosamide inhibition of Wnt/ß-catenin in BLBC and NATE cells Active Wnt/β-catenin signaling causes increased activation of TCF/LEF transcription factors. To confirm the inhibitory effect of Niclosamide on the Wnt/β-catenin pathway, we performed the signaling TOPflash luciferase reporter assay to test for inhibition of Wnt/β-catenin activity. 2LMP, SUM159, HCC1187 and HCC1143 adherent cells where transiently transfected with TOPflash and treated with Niclosamide as shown in Figure 4A . Niclosamide significantly blocked Wnt/β-catenin activity at levels greater then 60% in 2LMP, SUM159 and HCC1143 cell lines (p values = 0.0005, 0.002, 0.006) . HCC1187 Wnt/β-catenin TOPflash activity was only significantly inhibited in the presence of Wnt3A ligand (data not shown). Inhibition of Wnt/β-catenin was confirmed by Western blot analysis by examining the total levels of Wnt co-receptor LRP6, phosphorylated LRP6, free β-catenin, total β-catenin and Axin2 after 24 h treatment with Niclosamide (0.5, 0.25, 0.125 µM) on 2LMP adherent and NATE cells (Fig. 4B) . As shown in Figure 2B , increasing doses of Niclosamide reduced total LRP6 and p-LRP6 expression in both adherent and NATE cells for both 2LMP and HCC1187 cell lines. There was a dose-dependent reduction in the expression of total and free β -catenin with increasing levels of Niclosamide. Total and free β-catenin expression was inhibited in NATE cells with a 0.25 µM concentration of Niclosamide. Axin2 is a specific transcriptional target of the Wnt/β-catenin signaling pathway [37] . Increasing doses of Niclosamide in both adherent and NATE cells caused a reduction in Axin2. Niclosamide also showed inhibition of the Wnt/β-catenin pathway in patient sample UAB03 (Fig. 4D ).
Task 3c. In vitro combination treatment with TRA-8 and Niclosamide
All 4 BLBC cell lines showed inhibition of secondary tumorsphere formation, with Niclosamide concentrations resulting in half the maximal dose required for tumorsphere inhibition (IT 50 ) of 0.25 µM for 2LMP, 0.09 µM for HCC1143, and 0.175 µM for both HCC1187 and SUM159 (Fig.  5A ). Pre-treatment with Niclosamide followed by treatment with TRA-8 resulted in increased inhibition of secondary tumorsphere formation. Niclosamide and TRA-8 combined inhibited 80-90% of secondary tumorsphere formation relative to an average of 60% by Niclosamide alone and 40% by TRA-8 as single agent (p-value < 0.00007) (Fig. 5B) . Treatment with Niclosamide alone disrupted tumorsphere formation, with the most significant amount of disruption seen in the HCC1143 cell line (Fig. 5C ). Adherent 2LMP, SUM159, HCC1143 and HCC1187 cells were treated with Niclosamide and TRA-8 for 24 h and this resulted in decreased Wnt/β-catenin activity compared to untreated cells. For the 2LMP, SUM159 and HCC1143 cell lines, either agent alone produced greater then 50% reduction in TOPflash activity and the combination resulted in significantly greater reduction compared to Niclosamide treatment alone. The HCC1187 cell line treated with 0.25 ng/mL TRA-8 and 0.25 µM Niclosamide, only showed significant inhibition of Wnt activity compared to untreated controls ( 
To be completed

Aim #4:
To evaluate the in vivo therapeutic efficacy of anti-DR5 in combination with Niclosamide in xenograft models.
Task 4a. Ex vivo
Effect of ex vivo treatment of BrCSC enriched cells on tumorigenicity in NOD/SCID mice. 2LMP and SUM159 tumorspheres were treated with TRA-8, Niclosamide, or the combination and IgG control antibody for 3 h and implanted into the MFP of groups of five NOD/SCID mice. Table 2 Task 4c. In vivo treatment using various doses of Niclosamide in both 2LMP and HCC1187 BLBC orthotopic tumor animal models.
To be completed
Key research accomplishments:
• BrCSC marker expression is maintained for ~24 h after sorting and cells grown in mammosphere media/low attachment plates acquire elevated levels of ALDH activity by 12 h. This transient population was named non-adherent tumorsphere enriched (NATE).
• TRA-8 is not cytotoxic to normal breast cells or breast stem cells.
• BrCSC enriched populations have DR5 expression similar to parental cells.
• TRA-8 treatment of basal-like BrCSC populations activates caspase 8 and 3.
• TRA-8 treatment of BrCSC populations dramatically inhibits tumorsphere formation.
• BrCSC from 5 out of 8 cell lines were significantly more sensitive to TRA-8 then parental cells.
• Tumorigenicity of BrCSC was inhibited by treatment with TRA-8.
• Adherent and NATE cells from 2LMP, SUM159, HCC1187 and HCC1143 cell lines and patient pleural effusions showed that Niclosamide inhibited Wnt/β-catenin pathway activation, down regulated LRP6, and decreased downstream β-catenin signaling.
• MCF10 non-malignant cell line did not respond to treatment with Niclosamide.
• The combination of TRA-8 and Niclosamide showed additive to synergistic secondary tumorsphere inhibition and further reduced Wnt/β-catenin activity.
• Ex vivo studies using 2LMP and SUM159 cell lines showed the combination treatment with TRA-8 and Niclosamide produced greater inhibition of tumorigenicity.
• In vivo studies showed that intraperitoneal administration of Niclosamide in combination with TRA-8 produced increased growth suppression of established 2LMP orthotopic tumor xenografts. 
Conclusion:
Results described in this report indicate that targeting β -catenin in BLBC might be an effective means of increasing TRA-8 sensitivity. Combining TRA-8 with Niclosamide is an approach to ameliorate TRA-8 resistance in cancer cells by antagonizing the β-catenin pathway. Niclosamide is a well-studied drug in humans and is relatively inexpensive compared to other chemotherapeutic agents. The combination of these two well-tolerated drugs can be quickly translated into clinical trials, potentially helping BLBC patients who have very few treatment options available to them. This study provides valuable pre-clinical research results that gives important insight into using these novel agents in clinical trials in patients with BLBC. Inhibition of secondary tumorsphere formation in combination with niclosamide and TRA-8. NATE cells were pre-treated with niclosamide for 24 (0.25 µM), followed with treatment with TRA-8 for an additional 24 h (1 ng/mL 2LMP, 0.5 ng/mL SUM159, 25 ng/mL HCC1143 and 5 ng/mL HCC1187). Secondary tumorsphere inhibition was visually counted using a reticle eye piece (50-150 µm). (C) Phase contrast pictures of 2LMP and HCC1143 cell lines pre-treated with niclosamide (0.25 µM) for 24 h, followed by TRA-8 (1 ng/mL 2LMP, 25 ng/mL HCC1143) and the combination, scale bar (100 µm). All individual experiments were assayed in quadruplicates, values represent the mean relative to control and error bars represent SE from three independent experiments. * p< 0.007 
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